Lipoprotein-associated phospholipase A2 (Lp-PLA2)
| Cardiology Network |
 Discuss Lipoprotein-associated phospholipase A2 (Lp-PLA2) further in the WikiDoc Cardiology Network |
| Adult Congenital |
|---|
| Biomarkers |
| Cardiac Rehabilitation |
| Congestive Heart Failure |
| CT Angiography |
| Echocardiography |
| Electrophysiology |
| Cardiology General |
| Genetics |
| Health Economics |
| Hypertension |
| Interventional Cardiology |
| MRI |
| Nuclear Cardiology |
| Peripheral Arterial Disease |
| Prevention |
| Public Policy |
| Pulmonary Embolism |
| Stable Angina |
| Valvular Heart Disease |
| Vascular Medicine |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an enzyme that can modify low-density lipoproteins and may be involved in atherogenesis and the risk of coronary artery disease. In a nested case-control study, patients in the highest quintile of Lp-PLA2 levels had nearly twice the odds of coronary events compared with patients in the lowest quintile.